[Clinical characteristics and outcomes of 112 cardiovascular disease patients infected by 2019-nCoV].
Identifieur interne : 000896 ( PubMed/Curation ); précédent : 000895; suivant : 000897[Clinical characteristics and outcomes of 112 cardiovascular disease patients infected by 2019-nCoV].
Auteurs : Y D Peng [République populaire de Chine] ; K. Meng [République populaire de Chine] ; H Q Guan [République populaire de Chine] ; L. Leng [République populaire de Chine] ; R R Zhu [République populaire de Chine] ; B Y Wang [République populaire de Chine] ; M A He [République populaire de Chine] ; L X Cheng [République populaire de Chine] ; K. Huang [République populaire de Chine] ; Q T Zeng [République populaire de Chine]Source :
- Zhonghua xin xue guan bing za zhi [ 0253-3758 ] ; 2020.
Abstract
Objective: To explore the clinical characteristics and prognosis of the new coronavirus 2019-nCoV patients combined with cardiovascular disease (CVD). Methods: A retrospective analysis was performed on 112 COVID-19 patients with CVD admitted to the western district of Union Hospital in Wuhan, from January 20, 2020 to February 15, 2020. They were divided into critical group (ICU, n=16) and general group (n=96) according to the severity of the disease and patients were followed up to the clinical endpoint. The observation indicators included total blood count, C-reactive protein (CRP), arterial blood gas analysis, myocardial injury markers, coagulation function, liver and kidney function, electrolyte, procalcitonin (PCT), B-type natriuretic peptide (BNP), blood lipid, pulmonary CT and pathogen detection. Results: Compared with the general group, the lymphocyte count (0.74×10(9) (0.34×10(9), 0.94×10(9))/L vs. 0.99×10(9) (0.71×10(9), 1.29×10(9))/L, P=0.03) was extremely lower in the critical group, CRP (106.98 (81.57, 135.76) mg/L vs. 34.34 (9.55,76.54) mg/L, P<0.001) and PCT (0.20 (0.15,0.48) μg/L vs. 0.11 (0.06,0.20)μg/L, P<0.001) were significantly higher in the critical group. The BMI of the critical group was significantly higher than that of the general group (25.5 (23.0, 27.5) kg/m(2) vs. 22.0 (20.0, 24.0) kg/m(2), P=0.003). Patients were further divided into non-survivor group (17, 15.18%) group and survivor group (95, 84.82%). Among the non-survivors, there were 88.24% (15/17) patients with BMI> 25 kg/m(2), which was significantly higher than that of survivors (18.95% (18/95), P<0.001). Compared with the survived patients, oxygenation index (130 (102, 415) vs. 434 (410, 444), P<0.001) was significantly lower and lactic acid (1.70 (1.30, 3.00) mmol/L vs. 1.20 (1.10, 1.60) mmol/L, P<0.001) was significantly higher in the non-survivors. There was no significant difference in the proportion of ACEI/ARB medication between the critical group and the general group or between non-survivors and survivors (all P>0.05). Conclusion: COVID-19 patients combined with CVD are associated with a higher risk of mortality. Critical patients are characterized with lower lymphocyte counts. Higher BMI are more often seen in critical patients and non-survivor. ACEI/ARB use does not affect the morbidity and mortality of COVID-19 combined with CVD. Aggravating causes of death include fulminant inflammation, lactic acid accumulation and thrombotic events.
DOI: 10.3760/cma.j.cn112148-20200220-00105
PubMed: 32120458
Links toward previous steps (curation, corpus...)
- to stream PubMed, to step Corpus: Pour aller vers cette notice dans l'étape Curation :000896
Links to Exploration step
pubmed:32120458Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">[Clinical characteristics and outcomes of 112 cardiovascular disease patients infected by 2019-nCoV].</title><author><name sortKey="Peng, Y D" sort="Peng, Y D" uniqKey="Peng Y" first="Y D" last="Peng">Y D Peng</name><affiliation wicri:level="1"><nlm:affiliation>Department of Institute of Cardiovascular Diseases, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan 430022, China.</nlm:affiliation><country xml:lang="fr">République populaire de Chine</country><wicri:regionArea>Department of Institute of Cardiovascular Diseases, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan 430022</wicri:regionArea></affiliation></author><author><name sortKey="Meng, K" sort="Meng, K" uniqKey="Meng K" first="K" last="Meng">K. Meng</name><affiliation wicri:level="1"><nlm:affiliation>Department of Institute of Cardiovascular Diseases, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan 430022, China.</nlm:affiliation><country xml:lang="fr">République populaire de Chine</country><wicri:regionArea>Department of Institute of Cardiovascular Diseases, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan 430022</wicri:regionArea></affiliation></author><author><name sortKey="Guan, H Q" sort="Guan, H Q" uniqKey="Guan H" first="H Q" last="Guan">H Q Guan</name><affiliation wicri:level="1"><nlm:affiliation>Department of Institute of Cardiovascular Diseases, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan 430022, China.</nlm:affiliation><country xml:lang="fr">République populaire de Chine</country><wicri:regionArea>Department of Institute of Cardiovascular Diseases, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan 430022</wicri:regionArea></affiliation></author><author><name sortKey="Leng, L" sort="Leng, L" uniqKey="Leng L" first="L" last="Leng">L. Leng</name><affiliation wicri:level="1"><nlm:affiliation>Department of Institute of Cardiovascular Diseases, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan 430022, China.</nlm:affiliation><country xml:lang="fr">République populaire de Chine</country><wicri:regionArea>Department of Institute of Cardiovascular Diseases, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan 430022</wicri:regionArea></affiliation></author><author><name sortKey="Zhu, R R" sort="Zhu, R R" uniqKey="Zhu R" first="R R" last="Zhu">R R Zhu</name><affiliation wicri:level="1"><nlm:affiliation>Department of Institute of Cardiovascular Diseases, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan 430022, China.</nlm:affiliation><country xml:lang="fr">République populaire de Chine</country><wicri:regionArea>Department of Institute of Cardiovascular Diseases, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan 430022</wicri:regionArea></affiliation></author><author><name sortKey="Wang, B Y" sort="Wang, B Y" uniqKey="Wang B" first="B Y" last="Wang">B Y Wang</name><affiliation wicri:level="1"><nlm:affiliation>Department of Institute of Cardiovascular Diseases, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan 430022, China.</nlm:affiliation><country xml:lang="fr">République populaire de Chine</country><wicri:regionArea>Department of Institute of Cardiovascular Diseases, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan 430022</wicri:regionArea></affiliation></author><author><name sortKey="He, M A" sort="He, M A" uniqKey="He M" first="M A" last="He">M A He</name><affiliation wicri:level="1"><nlm:affiliation>School of Public Health, Tongji Medical College, Huazhong University of Science and Technology, Wuhan 430030, China.</nlm:affiliation><country xml:lang="fr">République populaire de Chine</country><wicri:regionArea>School of Public Health, Tongji Medical College, Huazhong University of Science and Technology, Wuhan 430030</wicri:regionArea></affiliation></author><author><name sortKey="Cheng, L X" sort="Cheng, L X" uniqKey="Cheng L" first="L X" last="Cheng">L X Cheng</name><affiliation wicri:level="1"><nlm:affiliation>Department of Institute of Cardiovascular Diseases, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan 430022, China.</nlm:affiliation><country xml:lang="fr">République populaire de Chine</country><wicri:regionArea>Department of Institute of Cardiovascular Diseases, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan 430022</wicri:regionArea></affiliation></author><author><name sortKey="Huang, K" sort="Huang, K" uniqKey="Huang K" first="K" last="Huang">K. Huang</name><affiliation wicri:level="1"><nlm:affiliation>Department of Institute of Cardiovascular Diseases, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan 430022, China.</nlm:affiliation><country xml:lang="fr">République populaire de Chine</country><wicri:regionArea>Department of Institute of Cardiovascular Diseases, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan 430022</wicri:regionArea></affiliation></author><author><name sortKey="Zeng, Q T" sort="Zeng, Q T" uniqKey="Zeng Q" first="Q T" last="Zeng">Q T Zeng</name><affiliation wicri:level="1"><nlm:affiliation>Department of Institute of Cardiovascular Diseases, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan 430022, China.</nlm:affiliation><country xml:lang="fr">République populaire de Chine</country><wicri:regionArea>Department of Institute of Cardiovascular Diseases, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan 430022</wicri:regionArea></affiliation></author></titleStmt><publicationStmt><idno type="wicri:source">PubMed</idno><date when="2020">2020</date><idno type="RBID">pubmed:32120458</idno><idno type="pmid">32120458</idno><idno type="doi">10.3760/cma.j.cn112148-20200220-00105</idno><idno type="wicri:Area/PubMed/Corpus">000896</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Corpus" wicri:corpus="PubMed">000896</idno><idno type="wicri:Area/PubMed/Curation">000896</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Curation">000896</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en">[Clinical characteristics and outcomes of 112 cardiovascular disease patients infected by 2019-nCoV].</title><author><name sortKey="Peng, Y D" sort="Peng, Y D" uniqKey="Peng Y" first="Y D" last="Peng">Y D Peng</name><affiliation wicri:level="1"><nlm:affiliation>Department of Institute of Cardiovascular Diseases, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan 430022, China.</nlm:affiliation><country xml:lang="fr">République populaire de Chine</country><wicri:regionArea>Department of Institute of Cardiovascular Diseases, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan 430022</wicri:regionArea></affiliation></author><author><name sortKey="Meng, K" sort="Meng, K" uniqKey="Meng K" first="K" last="Meng">K. Meng</name><affiliation wicri:level="1"><nlm:affiliation>Department of Institute of Cardiovascular Diseases, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan 430022, China.</nlm:affiliation><country xml:lang="fr">République populaire de Chine</country><wicri:regionArea>Department of Institute of Cardiovascular Diseases, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan 430022</wicri:regionArea></affiliation></author><author><name sortKey="Guan, H Q" sort="Guan, H Q" uniqKey="Guan H" first="H Q" last="Guan">H Q Guan</name><affiliation wicri:level="1"><nlm:affiliation>Department of Institute of Cardiovascular Diseases, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan 430022, China.</nlm:affiliation><country xml:lang="fr">République populaire de Chine</country><wicri:regionArea>Department of Institute of Cardiovascular Diseases, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan 430022</wicri:regionArea></affiliation></author><author><name sortKey="Leng, L" sort="Leng, L" uniqKey="Leng L" first="L" last="Leng">L. Leng</name><affiliation wicri:level="1"><nlm:affiliation>Department of Institute of Cardiovascular Diseases, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan 430022, China.</nlm:affiliation><country xml:lang="fr">République populaire de Chine</country><wicri:regionArea>Department of Institute of Cardiovascular Diseases, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan 430022</wicri:regionArea></affiliation></author><author><name sortKey="Zhu, R R" sort="Zhu, R R" uniqKey="Zhu R" first="R R" last="Zhu">R R Zhu</name><affiliation wicri:level="1"><nlm:affiliation>Department of Institute of Cardiovascular Diseases, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan 430022, China.</nlm:affiliation><country xml:lang="fr">République populaire de Chine</country><wicri:regionArea>Department of Institute of Cardiovascular Diseases, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan 430022</wicri:regionArea></affiliation></author><author><name sortKey="Wang, B Y" sort="Wang, B Y" uniqKey="Wang B" first="B Y" last="Wang">B Y Wang</name><affiliation wicri:level="1"><nlm:affiliation>Department of Institute of Cardiovascular Diseases, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan 430022, China.</nlm:affiliation><country xml:lang="fr">République populaire de Chine</country><wicri:regionArea>Department of Institute of Cardiovascular Diseases, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan 430022</wicri:regionArea></affiliation></author><author><name sortKey="He, M A" sort="He, M A" uniqKey="He M" first="M A" last="He">M A He</name><affiliation wicri:level="1"><nlm:affiliation>School of Public Health, Tongji Medical College, Huazhong University of Science and Technology, Wuhan 430030, China.</nlm:affiliation><country xml:lang="fr">République populaire de Chine</country><wicri:regionArea>School of Public Health, Tongji Medical College, Huazhong University of Science and Technology, Wuhan 430030</wicri:regionArea></affiliation></author><author><name sortKey="Cheng, L X" sort="Cheng, L X" uniqKey="Cheng L" first="L X" last="Cheng">L X Cheng</name><affiliation wicri:level="1"><nlm:affiliation>Department of Institute of Cardiovascular Diseases, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan 430022, China.</nlm:affiliation><country xml:lang="fr">République populaire de Chine</country><wicri:regionArea>Department of Institute of Cardiovascular Diseases, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan 430022</wicri:regionArea></affiliation></author><author><name sortKey="Huang, K" sort="Huang, K" uniqKey="Huang K" first="K" last="Huang">K. Huang</name><affiliation wicri:level="1"><nlm:affiliation>Department of Institute of Cardiovascular Diseases, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan 430022, China.</nlm:affiliation><country xml:lang="fr">République populaire de Chine</country><wicri:regionArea>Department of Institute of Cardiovascular Diseases, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan 430022</wicri:regionArea></affiliation></author><author><name sortKey="Zeng, Q T" sort="Zeng, Q T" uniqKey="Zeng Q" first="Q T" last="Zeng">Q T Zeng</name><affiliation wicri:level="1"><nlm:affiliation>Department of Institute of Cardiovascular Diseases, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan 430022, China.</nlm:affiliation><country xml:lang="fr">République populaire de Chine</country><wicri:regionArea>Department of Institute of Cardiovascular Diseases, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan 430022</wicri:regionArea></affiliation></author></analytic><series><title level="j">Zhonghua xin xue guan bing za zhi</title><idno type="ISSN">0253-3758</idno><imprint><date when="2020" type="published">2020</date></imprint></series></biblStruct></sourceDesc></fileDesc><profileDesc><textClass></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en"><b>Objective:</b> To explore the clinical characteristics and prognosis of the new coronavirus 2019-nCoV patients combined with cardiovascular disease (CVD). <b>Methods:</b> A retrospective analysis was performed on 112 COVID-19 patients with CVD admitted to the western district of Union Hospital in Wuhan, from January 20, 2020 to February 15, 2020. They were divided into critical group (ICU, <i>n</i>=16) and general group (<i>n</i>=96) according to the severity of the disease and patients were followed up to the clinical endpoint. The observation indicators included total blood count, C-reactive protein (CRP), arterial blood gas analysis, myocardial injury markers, coagulation function, liver and kidney function, electrolyte, procalcitonin (PCT), B-type natriuretic peptide (BNP), blood lipid, pulmonary CT and pathogen detection. <b>Results:</b> Compared with the general group, the lymphocyte count (0.74×10(9) (0.34×10(9), 0.94×10(9))/L vs. 0.99×10(9) (0.71×10(9), 1.29×10(9))/L, <i>P</i>=0.03) was extremely lower in the critical group, CRP (106.98 (81.57, 135.76) mg/L vs. 34.34 (9.55,76.54) mg/L, <i>P</i><0.001) and PCT (0.20 (0.15,0.48) μg/L vs. 0.11 (0.06,0.20)μg/L, <i>P</i><0.001) were significantly higher in the critical group. The BMI of the critical group was significantly higher than that of the general group (25.5 (23.0, 27.5) kg/m(2) vs. 22.0 (20.0, 24.0) kg/m(2), <i>P</i>=0.003). Patients were further divided into non-survivor group (17, 15.18%) group and survivor group (95, 84.82%). Among the non-survivors, there were 88.24% (15/17) patients with BMI> 25 kg/m(2), which was significantly higher than that of survivors (18.95% (18/95), <i>P</i><0.001). Compared with the survived patients, oxygenation index (130 (102, 415) vs. 434 (410, 444), <i>P</i><0.001) was significantly lower and lactic acid (1.70 (1.30, 3.00) mmol/L vs. 1.20 (1.10, 1.60) mmol/L, <i>P</i><0.001) was significantly higher in the non-survivors. There was no significant difference in the proportion of ACEI/ARB medication between the critical group and the general group or between non-survivors and survivors (all <i>P</i>>0.05). <b>Conclusion:</b> COVID-19 patients combined with CVD are associated with a higher risk of mortality. Critical patients are characterized with lower lymphocyte counts. Higher BMI are more often seen in critical patients and non-survivor. ACEI/ARB use does not affect the morbidity and mortality of COVID-19 combined with CVD. Aggravating causes of death include fulminant inflammation, lactic acid accumulation and thrombotic events.</div></front></TEI><pubmed><MedlineCitation Status="Publisher" Owner="NLM"><PMID Version="1">32120458</PMID><DateRevised><Year>2020</Year><Month>03</Month><Day>02</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Print">0253-3758</ISSN><JournalIssue CitedMedium="Print"><Volume>48</Volume><Issue>0</Issue><PubDate><Year>2020</Year><Month>Mar</Month><Day>02</Day></PubDate></JournalIssue><Title>Zhonghua xin xue guan bing za zhi</Title><ISOAbbreviation>Zhonghua Xin Xue Guan Bing Za Zhi</ISOAbbreviation></Journal><ArticleTitle>[Clinical characteristics and outcomes of 112 cardiovascular disease patients infected by 2019-nCoV].</ArticleTitle><Pagination><MedlinePgn>E004</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.3760/cma.j.cn112148-20200220-00105</ELocationID><Abstract><AbstractText><b>Objective:</b> To explore the clinical characteristics and prognosis of the new coronavirus 2019-nCoV patients combined with cardiovascular disease (CVD). <b>Methods:</b> A retrospective analysis was performed on 112 COVID-19 patients with CVD admitted to the western district of Union Hospital in Wuhan, from January 20, 2020 to February 15, 2020. They were divided into critical group (ICU, <i>n</i>=16) and general group (<i>n</i>=96) according to the severity of the disease and patients were followed up to the clinical endpoint. The observation indicators included total blood count, C-reactive protein (CRP), arterial blood gas analysis, myocardial injury markers, coagulation function, liver and kidney function, electrolyte, procalcitonin (PCT), B-type natriuretic peptide (BNP), blood lipid, pulmonary CT and pathogen detection. <b>Results:</b> Compared with the general group, the lymphocyte count (0.74×10(9) (0.34×10(9), 0.94×10(9))/L vs. 0.99×10(9) (0.71×10(9), 1.29×10(9))/L, <i>P</i>=0.03) was extremely lower in the critical group, CRP (106.98 (81.57, 135.76) mg/L vs. 34.34 (9.55,76.54) mg/L, <i>P</i><0.001) and PCT (0.20 (0.15,0.48) μg/L vs. 0.11 (0.06,0.20)μg/L, <i>P</i><0.001) were significantly higher in the critical group. The BMI of the critical group was significantly higher than that of the general group (25.5 (23.0, 27.5) kg/m(2) vs. 22.0 (20.0, 24.0) kg/m(2), <i>P</i>=0.003). Patients were further divided into non-survivor group (17, 15.18%) group and survivor group (95, 84.82%). Among the non-survivors, there were 88.24% (15/17) patients with BMI> 25 kg/m(2), which was significantly higher than that of survivors (18.95% (18/95), <i>P</i><0.001). Compared with the survived patients, oxygenation index (130 (102, 415) vs. 434 (410, 444), <i>P</i><0.001) was significantly lower and lactic acid (1.70 (1.30, 3.00) mmol/L vs. 1.20 (1.10, 1.60) mmol/L, <i>P</i><0.001) was significantly higher in the non-survivors. There was no significant difference in the proportion of ACEI/ARB medication between the critical group and the general group or between non-survivors and survivors (all <i>P</i>>0.05). <b>Conclusion:</b> COVID-19 patients combined with CVD are associated with a higher risk of mortality. Critical patients are characterized with lower lymphocyte counts. Higher BMI are more often seen in critical patients and non-survivor. ACEI/ARB use does not affect the morbidity and mortality of COVID-19 combined with CVD. Aggravating causes of death include fulminant inflammation, lactic acid accumulation and thrombotic events.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Peng</LastName><ForeName>Y D</ForeName><Initials>YD</Initials><AffiliationInfo><Affiliation>Department of Institute of Cardiovascular Diseases, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan 430022, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Meng</LastName><ForeName>K</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>Department of Institute of Cardiovascular Diseases, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan 430022, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Guan</LastName><ForeName>H Q</ForeName><Initials>HQ</Initials><AffiliationInfo><Affiliation>Department of Institute of Cardiovascular Diseases, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan 430022, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Leng</LastName><ForeName>L</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>Department of Institute of Cardiovascular Diseases, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan 430022, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zhu</LastName><ForeName>R R</ForeName><Initials>RR</Initials><AffiliationInfo><Affiliation>Department of Institute of Cardiovascular Diseases, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan 430022, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wang</LastName><ForeName>B Y</ForeName><Initials>BY</Initials><AffiliationInfo><Affiliation>Department of Institute of Cardiovascular Diseases, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan 430022, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>He</LastName><ForeName>M A</ForeName><Initials>MA</Initials><AffiliationInfo><Affiliation>School of Public Health, Tongji Medical College, Huazhong University of Science and Technology, Wuhan 430030, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Cheng</LastName><ForeName>L X</ForeName><Initials>LX</Initials><AffiliationInfo><Affiliation>Department of Institute of Cardiovascular Diseases, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan 430022, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Huang</LastName><ForeName>K</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>Department of Institute of Cardiovascular Diseases, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan 430022, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zeng</LastName><ForeName>Q T</ForeName><Initials>QT</Initials><AffiliationInfo><Affiliation>Department of Institute of Cardiovascular Diseases, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan 430022, China.</Affiliation></AffiliationInfo></Author></AuthorList><Language>chi</Language><PublicationTypeList><PublicationType UI="D004740">English Abstract</PublicationType><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2020</Year><Month>03</Month><Day>02</Day></ArticleDate></Article><MedlineJournalInfo><Country>China</Country><MedlineTA>Zhonghua Xin Xue Guan Bing Za Zhi</MedlineTA><NlmUniqueID>7910682</NlmUniqueID><ISSNLinking>0253-3758</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><OtherAbstract Type="Publisher" Language="chi"><AbstractText><b>目的：</b> 研究心血管病（CVD）患者罹患新型冠状病毒肺炎（COVID-19）后的临床特点及转归。 <b>方法：</b> 回顾性分析2020年1月20日至2020年2月15日入武汉协和医院西院的112例COVID-19合并CVD患者，按病情严重程度分为危重组（<i>n</i>=16）和普通组（<i>n</i>=96），观察随访至临床终点。观察指标包括全血细胞计数、C反应蛋白（CRP）、动脉血气分析、心肌损伤标志物、凝血功能、肝肾功能、电解质、降钙素原（PCT）、B型利钠肽（BNP）、血脂、肺部CT及病原学检测。 <b>结果：</b> 与普通组比较，危重组患者淋巴细胞计数[0.74×10(9)（0.34×10(9)，0.94×10(9)）/L比0.99×10(9)（0.71×10(9)，1.29×10(9)）/L，<i>P</i>=0.03]较低，CRP[106.98（81.57，135.76）mg/L比34.34（9.55，76.54）mg/L，<i>P</i><0.001]和PCT[0.20（0.15，0.48）μg/L比0.11（0.06，0.20）μg/L，<i>P</i><0.001]较高；危重组体重指数（BMI）明显高于普通组[25.5（23.0，27.5）kg/m(2)比22.0（20.0， 24.0）kg/m(2)，<i>P</i>=0.003]。112例患者中全因死亡17例（15.18%），治愈95例（84.82%）。死亡患者中，BMI>25 kg/m(2)患者占88.24%（15/17），明显高于治愈患者的18.95%（18/95，<i>P</i><0.001）。和治愈患者比较，死亡患者血乳酸[1.70（1.30，3.00）mmol/L比1.20（1.10，1.60）mmol/L，<i>P</i><0.001]较高，氧合指数[130（102，415）比434（410，444），<i>P</i><0.001]明显偏低。使用ACEI/ARB的患者比例无论在危重组与普通组间还是在死亡与治愈患者间比较，差异均无统计学意义（<i>P</i>均>0.05）。 <b>结论：</b> COVID-19合并CVD病情重病死率较高。危重患者淋巴细胞偏低，危重患者和死亡患者BMI值偏高。ACEI/ARB不影响COVID-19合并CVD患者的发病率和病死率。加剧患者死亡的原因可能与炎症反应、乳酸堆积酸中毒以及恶性心血管事件有关。.</AbstractText></OtherAbstract><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">COVID-19</Keyword><Keyword MajorTopicYN="N">Cardiovascular diseases</Keyword><Keyword MajorTopicYN="N">Treatment outcome</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2020</Year><Month>3</Month><Day>3</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2020</Year><Month>3</Month><Day>4</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2020</Year><Month>3</Month><Day>4</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>aheadofprint</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">32120458</ArticleId><ArticleId IdType="doi">10.3760/cma.j.cn112148-20200220-00105</ArticleId></ArticleIdList></PubmedData></pubmed></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Sante/explor/CovidV2/Data/PubMed/Curation
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000896 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/PubMed/Curation/biblio.hfd -nk 000896 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Sante
|area= CovidV2
|flux= PubMed
|étape= Curation
|type= RBID
|clé= pubmed:32120458
|texte= [Clinical characteristics and outcomes of 112 cardiovascular disease patients infected by 2019-nCoV].
}}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/PubMed/Curation/RBID.i -Sk "pubmed:32120458" \
| HfdSelect -Kh $EXPLOR_AREA/Data/PubMed/Curation/biblio.hfd \
| NlmPubMed2Wicri -a CovidV2
| This area was generated with Dilib version V0.6.33. |  |